Northstar Ventures
Northstar Ventures is a venture capital firm based in Newcastle upon Tyne, United Kingdom. It provides direct investments in early-stage and growth companies and also participates in fund of funds, including private equity funds, accelerators, and incubators. The firm targets sectors such as digital media, entertainment technology, music services, data, telecommunications, clean technology, healthcare and biotechnology, energy, climate tech, computer games, and related technologies. It focuses its activity in the North East region of England, especially County Durham, Northumberland, and Tyne and Wear, and supports portfolio companies with strategic value through its network of university partners, funders, and experienced non-executive directors. Typical investments range from small seed or pre-seed rounds to larger growth rounds, with co-investment alongside other investors. Northstar Ventures emphasizes helping innovative companies create talent, jobs, and growth in the region, contributing to the local innovation ecosystem.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Health Diagnostics
Nanovery
Venture Round in 2025
Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.
NunaBio
Seed Round in 2024
NunaBio is a privately-owned specialist DNA development company based in England, United Kingdom. The company focuses on chemical and biological technologies, providing a diverse array of products and services, including long and short deoxyribonucleic acid products available in various scales, from microgram to gram. NunaBio is involved in contract research and development, as well as manufacturing, offering capabilities in cell therapies, vaccines, diagnostics, gene therapies, and advanced DNA biosensing. By delivering these innovative solutions, NunaBio aims to support healthcare professionals in their efforts to treat patients effectively.
LightOx
Venture Round in 2024
LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.
Nanovery
Seed Round in 2023
Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.
NunaBio
Seed Round in 2023
NunaBio is a privately-owned specialist DNA development company based in England, United Kingdom. The company focuses on chemical and biological technologies, providing a diverse array of products and services, including long and short deoxyribonucleic acid products available in various scales, from microgram to gram. NunaBio is involved in contract research and development, as well as manufacturing, offering capabilities in cell therapies, vaccines, diagnostics, gene therapies, and advanced DNA biosensing. By delivering these innovative solutions, NunaBio aims to support healthcare professionals in their efforts to treat patients effectively.
Manus Neurodynamica
Series A in 2023
Founded in 2008, Manus Neurodynamica specializes in medical diagnostic technologies for neuromotor impairments. Its primary product is a non-invasive device designed to support early diagnostics and monitoring of Parkinson's disease, with applications in academic research, pharmaceutical studies, and non-medical uses.
Asaren
Venture Round in 2023
Asaren manages the mental health needs of their blue-chip clients' employees, with industries ranging from banking, energy, retail, and many others. They provide triage assessment, DNA testing, and online consultation with medical professionals.
Nanovery
Series A in 2022
Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.
Manus Neurodynamica
Seed Round in 2022
Founded in 2008, Manus Neurodynamica specializes in medical diagnostic technologies for neuromotor impairments. Its primary product is a non-invasive device designed to support early diagnostics and monitoring of Parkinson's disease, with applications in academic research, pharmaceutical studies, and non-medical uses.
AMLo Biosciences
Venture Round in 2022
AMLo Biosciences Ltd is a biotechnology company based in Newcastle upon Tyne, United Kingdom, focused on developing diagnostic solutions for melanoma. Incorporated in 2017, the company has created a diagnostic kit that utilizes the AMBLor test, which accurately predicts the risk of disease progression in patients with early AJCC Stage I and Stage II melanoma. This test identifies two specific proteins in the skin overlying the primary tumor that are typically lost in high-risk melanoma cases. By providing a reliable prognostic assessment, AMLo aims to help stratify patients for appropriate treatment and follow-up, ultimately reducing the psychological burden on patients and decreasing healthcare costs associated with unnecessary surveillance.
Arquer Diagnostics
Convertible Note in 2022
Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.
LightOx
Pre Seed Round in 2021
LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.
Glycoscoredx
Pre Seed Round in 2021
Glycoscoredx specializes in diagnostic solutions for prostate cancer, offering a blood test that utilizes a unique combination of biomarkers to accurately identify clinically significant cases of the disease. This innovative approach helps reduce the incidence of late diagnoses and minimizes unnecessary invasive procedures, such as prostate-tissue biopsies, by ruling out cancer in many patients. By delivering reliable testing options, Glycoscoredx aims to enhance patient outcomes and support early detection efforts, thus enabling healthcare providers to focus on individuals at a higher risk for aggressive prostate cancer. The company addresses customer inquiries through various channels, including phone, email, and online applications.
Nanovery
Seed Round in 2021
Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.
Arquer Diagnostics
Series B in 2019
Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.
AMLo Biosciences
Seed Round in 2018
AMLo Biosciences Ltd is a biotechnology company based in Newcastle upon Tyne, United Kingdom, focused on developing diagnostic solutions for melanoma. Incorporated in 2017, the company has created a diagnostic kit that utilizes the AMBLor test, which accurately predicts the risk of disease progression in patients with early AJCC Stage I and Stage II melanoma. This test identifies two specific proteins in the skin overlying the primary tumor that are typically lost in high-risk melanoma cases. By providing a reliable prognostic assessment, AMLo aims to help stratify patients for appropriate treatment and follow-up, ultimately reducing the psychological burden on patients and decreasing healthcare costs associated with unnecessary surveillance.
MindMate
Pre Seed Round in 2015
MindMate is a mobile application designed to empower individuals living with Alzheimer's and dementia. It offers interactive games, physical exercises, nutrition advice, music, and television content to stimulate cognitive abilities and improve self-management skills. Serving users worldwide, MindMate was founded in Glasgow, UK in 2015.
Arquer Diagnostics
Venture Round in 2015
Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.
Reinnervate
Venture Round in 2014
Reinnervate Limited is a biotechnology company based in Durham, United Kingdom, established in 2002. It specializes in the development of technologies that enhance research into cell growth and function in vitro, with a particular focus on stem cell biology. The company creates and markets 3D cell-culture products that enable researchers to establish assays and biological models that closely simulate in-vivo cell growth. Reinnervate's innovations also facilitate the control of stem cell differentiation and the formation of specific tissue types, contributing to the development of diagnostics and treatments for neuro-degenerative diseases.
Arquer Diagnostics
Seed Round in 2014
Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.
Arnia
Seed Round in 2013
Arnia Limited is a company based in Newcastle Upon Tyne, United Kingdom, that specializes in hive monitoring technology for beekeepers. Established in 2009, Arnia offers innovative solutions that measure daily bee activity, health, and environmental conditions such as temperature and rainfall. The company integrates environmental sensors and acoustic analysis within a single device, allowing beekeepers to monitor their hives remotely via a web interface or mobile application. This technology not only facilitates real-time data collection but also aims to enhance the understanding of bee populations, contributing to the vital relationship between humans and bees. Arnia is committed to advancing research in bee health and behavior, and it claims to possess the largest database of bee behavior globally. The company is actively pursuing patent protection for its unique technological innovations.
Arnia
Seed Round in 2013
Arnia Limited is a company based in Newcastle Upon Tyne, United Kingdom, that specializes in hive monitoring technology for beekeepers. Established in 2009, Arnia offers innovative solutions that measure daily bee activity, health, and environmental conditions such as temperature and rainfall. The company integrates environmental sensors and acoustic analysis within a single device, allowing beekeepers to monitor their hives remotely via a web interface or mobile application. This technology not only facilitates real-time data collection but also aims to enhance the understanding of bee populations, contributing to the vital relationship between humans and bees. Arnia is committed to advancing research in bee health and behavior, and it claims to possess the largest database of bee behavior globally. The company is actively pursuing patent protection for its unique technological innovations.
Reinnervate
Venture Round in 2013
Reinnervate Limited is a biotechnology company based in Durham, United Kingdom, established in 2002. It specializes in the development of technologies that enhance research into cell growth and function in vitro, with a particular focus on stem cell biology. The company creates and markets 3D cell-culture products that enable researchers to establish assays and biological models that closely simulate in-vivo cell growth. Reinnervate's innovations also facilitate the control of stem cell differentiation and the formation of specific tissue types, contributing to the development of diagnostics and treatments for neuro-degenerative diseases.
IBEX Innovations
Venture Round in 2013
IBEX Innovations develops innovative X-ray detector technology that generates high sensitivity materials information from standard detectors. Its core product, IBEX multi absorption plate (MAP) technology, integrates detectors to provide material insights while maintaining speed and resolution characteristics of underlying sensors. Applications include bone mineral density measurement, electronics inspection, food safety, and security screening.
Arquer Diagnostics
Seed Round in 2012
Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.
Protein Fit
Seed Round in 2012
Protein Fit
Arnia
Seed Round in 2012
Arnia Limited is a company based in Newcastle Upon Tyne, United Kingdom, that specializes in hive monitoring technology for beekeepers. Established in 2009, Arnia offers innovative solutions that measure daily bee activity, health, and environmental conditions such as temperature and rainfall. The company integrates environmental sensors and acoustic analysis within a single device, allowing beekeepers to monitor their hives remotely via a web interface or mobile application. This technology not only facilitates real-time data collection but also aims to enhance the understanding of bee populations, contributing to the vital relationship between humans and bees. Arnia is committed to advancing research in bee health and behavior, and it claims to possess the largest database of bee behavior globally. The company is actively pursuing patent protection for its unique technological innovations.
MyGenomics
Seed Round in 2012
MyGenomics offers DNA tests for determining optimum diet and exercise plan for weight management and fitness.
IBEX Innovations
Seed Round in 2012
IBEX Innovations develops innovative X-ray detector technology that generates high sensitivity materials information from standard detectors. Its core product, IBEX multi absorption plate (MAP) technology, integrates detectors to provide material insights while maintaining speed and resolution characteristics of underlying sensors. Applications include bone mineral density measurement, electronics inspection, food safety, and security screening.
Reinnervate
Series B in 2011
Reinnervate Limited is a biotechnology company based in Durham, United Kingdom, established in 2002. It specializes in the development of technologies that enhance research into cell growth and function in vitro, with a particular focus on stem cell biology. The company creates and markets 3D cell-culture products that enable researchers to establish assays and biological models that closely simulate in-vivo cell growth. Reinnervate's innovations also facilitate the control of stem cell differentiation and the formation of specific tissue types, contributing to the development of diagnostics and treatments for neuro-degenerative diseases.
MyGenomics
Seed Round in 2011
MyGenomics offers DNA tests for determining optimum diet and exercise plan for weight management and fitness.
Geneius Laboratories
Seed Round in 2011
Geneius Laboratories is an independent, science-led organization that specializes in safeguarding customer brands through comprehensive support in manufacturing and supply chain processes. The company offers consultancy, research, and efficient analytical testing services, leveraging advanced DNA technology to identify and analyze microorganisms in food products. By focusing on delivering reliable and accurate results, Geneius Laboratories ensures that clients receive total reassurance regarding the integrity and safety of their products.
Arnia
Seed Round in 2011
Arnia Limited is a company based in Newcastle Upon Tyne, United Kingdom, that specializes in hive monitoring technology for beekeepers. Established in 2009, Arnia offers innovative solutions that measure daily bee activity, health, and environmental conditions such as temperature and rainfall. The company integrates environmental sensors and acoustic analysis within a single device, allowing beekeepers to monitor their hives remotely via a web interface or mobile application. This technology not only facilitates real-time data collection but also aims to enhance the understanding of bee populations, contributing to the vital relationship between humans and bees. Arnia is committed to advancing research in bee health and behavior, and it claims to possess the largest database of bee behavior globally. The company is actively pursuing patent protection for its unique technological innovations.
Geneius Laboratories
Seed Round in 2010
Geneius Laboratories is an independent, science-led organization that specializes in safeguarding customer brands through comprehensive support in manufacturing and supply chain processes. The company offers consultancy, research, and efficient analytical testing services, leveraging advanced DNA technology to identify and analyze microorganisms in food products. By focusing on delivering reliable and accurate results, Geneius Laboratories ensures that clients receive total reassurance regarding the integrity and safety of their products.
Reinnervate
Series A in 2010
Reinnervate Limited is a biotechnology company based in Durham, United Kingdom, established in 2002. It specializes in the development of technologies that enhance research into cell growth and function in vitro, with a particular focus on stem cell biology. The company creates and markets 3D cell-culture products that enable researchers to establish assays and biological models that closely simulate in-vivo cell growth. Reinnervate's innovations also facilitate the control of stem cell differentiation and the formation of specific tissue types, contributing to the development of diagnostics and treatments for neuro-degenerative diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.